Related Experiment Video
Updated: Aug 30, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Demystifying FluMist, a new intranasal, live influenza vaccine
1Department of Infectious Diseases, The Cleveland Clinic Foundation, OH 44195, USA. mossads@ccf.org
Abstract:
FluMist--a cold-adapted, live-attenuated, trivalent, intranasal influenza virus vaccine approved by the US Food and Drug Administration on June 17, 2003--has been shown to be safe and effective, but its role in the general prevention of influenza is yet to be defined. Intranasal administration is expected to be more acceptable than parenteral, particularly in children, but the potential for the shedding of live virus may pose a risk to anyone with a compromised immune system.
Related Concept Videos
Influenza
Inhibitors Of Virion Release

